Biogen Cuts Profit Guidance After Deals to Bolster Pipeline (1)

Biogen Inc. cut its full-year profit guidance on higher costs from deals the company has been doing to offset the decline of its aging multiple sclerosis drugs.

The drugmaker now expects 2025 earnings of $14.50 to $15 a share, down from a prior forecast of $15.50 to $16, it said in a statement Thursday. The shares fell 3.6% in trading before US exchanges opened.

The lower profit outlook reflects costs from recent transactions, including an $85 million payment to buy Alcyone Therapeutics, which developed a device to simplify spinal drug delivery, and a $70 million payment to license an ...